11-Beta hydroxysteroid dehydrogenase
|
|
It has been suggested that this article or section be merged with 11beta-hydroxysteroid dehydrogenase. (Discuss) Proposed since April 2010. |
11β-Hydroxysteroid dehydrogenase (HSD-11β or 11β-HSD) is the name of a family of enzymes that catalyze the conversion of inert 11 keto-products (cortisone) to active cortisol, or vice versa,[1] thus regulating the access of glucocorticoids to the steroid receptors.
Contents |
[edit] Function
Cortisol, a glucocorticoid, binds the glucocorticoid receptor. However, because of its molecular similarity to aldosterone it is also capable of binding the mineralcorticoid receptor. Both aldosterone and cortisol have a similar affinity for the mineralocorticoid receptor; however, there is vastly more cortisol in circulation than aldosterone. To prevent over-stimulation of the mineralocorticoid receptor by cortisol, HSD-11β converts the biologically active cortisol to the inactive cortisone, which can no longer bind to the mineralocorticoid receptor. HSD-11β co-localizes with intracellular adrenal steroid receptors. Licorice or Carbenoxolone , which contains glycyrrhetinic acid, can inhibit 11β-HSD and lead to a mineralocorticoid excess syndrome.
[edit] Isoforms
In humans, there are two HSD11B isoforms:[2][3]
| HSD11B1 | NADPH-dependent | Highly expressed in key metabolic tissues including liver, adipose tissue, and the central nervous system. | In these tissues, HSD11B1 reduces cortisone to the active hormone cortisol that activates glucocorticoid receptors. |
| HSD11B2 | NAD+-dependent | Expressed in aldosterone-selective tissues,including colon, salivary glands, and placenta. | In these tissues, HSD11B2 oxidizes cortisol to cortisone and prevents illicit activation of the mineralocorticoid receptor. |
Inhibition of HSD11B1 has been suggested as a possible therapy for treatment of obesity and metabolic syndrome.[3]
[edit] See also
[edit] References
- ^ Seckl JR, Walker BR (April 2001). "Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action". Endocrinology 142 (4): 1371–6. doi:10.1210/en.142.4.1371. PMID 11250914. http://endo.endojournals.org/cgi/pmidlookup?view=long&pmid=11250914.
- ^ Seckl JR (January 1997). "11beta-Hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?". Front Neuroendocrinol 18 (1): 49–99. doi:10.1006/frne.1996.0143. PMID 9000459. http://linkinghub.elsevier.com/retrieve/pii/S0091-3022(96)90143-0.
- ^ a b Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP (2009). "Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis". The Journal of Clinical Endocrinology and Metabolism 94 (8): 2692–2701. doi:10.1210/jc.2009-0370. PMID 19470627. http://jcem.endojournals.org/cgi/content/full/94/8/2692.
[edit] External links
|
|||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||